Pharma stocks fall as Trump suggests high tariffs, up to 100%.
Pharma stocks saw a sharp decline after news that Donald Trump may introduce heavy tariffs on drug companies. These tariffs could go as high as 100% to 200%, which has created fear among investors.
Because of this, many pharma shares came under selling pressure. Stocks like Sun Pharmaceutical Industries, Divi’s Laboratories, and Biocon fell up to 4% during the day.
The pharma index also dropped more than 5% and continued its losing streak for the fourth straight session. This shows that the entire sector is under pressure due to global policy concerns.
What Happened in the Market?
The fall in pharma stocks is mainly linked to reports that the US government may soon announce tariffs on companies that do not agree to lower drug prices.
This move is part of a larger plan to:
- Reduce medicine costs in the US
- Shift manufacturing to the US
As a result, investors started selling pharma stocks due to uncertainty.
Why Are Pharma Stocks Falling?
1. Tariff Threat from the US
The biggest reason behind the fall is the possible tariff announcement. Companies that do not meet US conditions may face heavy duties.
2. Impact on Global Pharma Companies
Some companies like:
- Pfizer Inc.
- Eli Lilly and Company
has already signed agreements and received relief for three years.
However, companies without such agreements may be affected the most.
3. Pressure on Profits
If tariffs are imposed:
- Export costs will increase
- Profit margins may shrink
- Demand could slow down
This is why investors are reacting negatively.
Which Stocks Were Affected?
Here are some of the major stocks that declined:
- Biocon: Down up to 4%
- Ipca Laboratories: Down around 3.8%
- Torrent Pharmaceuticals: Down around 3.6%
- Sun Pharma: Down over 3%
- Divi’s Labs: Down over 2%
Almost all pharma stocks traded in the red.
What is the Section 232 Investigation?
The tariff plan is linked to Section 232 of the Trade Expansion Act.
This rule allows the US government to:
- Investigate imports
- Impose tariffs for national security reasons
This could significantly impact global pharmaceutical trade.
What Should Investors Do Now?
1. Stay Calm
Avoid panic selling. Market reactions can be temporary.
2. Follow Updates
Keep an eye on official announcements and company responses.
3. Focus on Strong Businesses
Companies with strong fundamentals and diversified markets may handle this situation better.
Conclusion
Pharma stocks are currently under pressure due to tariff concerns from the US. While the situation is uncertain, investors should stay informed and avoid emotional decisions. The next move in the market will depend on how these policies are implemented.
